FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

Under US law, compounding pharmacies can make and sell patent ... and other obesity therapies like Novo Nordisk's Wegovy (semaglutide), which remains on the shortages list. After deciding that ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Tirzepatide and semaglutide both belong to a class of drugs known as GLP-1s. Compounding pharmacies have been producing copycat versions of the drugs while they have been in short supply.

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

With tirzepatide and its Novo Nordisk rival semaglutide facing extended ... But under the FDA’s compounding standards, state-licensed pharmacies under Section 503A of the Food, Drug and Cosmetic ...